Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults

2020479 citationsJournal Articlebronze Open Access

Authors

Robin Foà · Fondazione Gimema Onlus

Renato Bassan · Fondazione Gimema Onlus

Antonella Vitale · Fondazione Gimema Onlus

Loredana Elia · Fondazione Gimema Onlus

Alfonso Piciocchi · Fondazione Gimema Onlus

Maria Cristina Puzzolo · Fondazione Gimema Onlus

Martina Canichella ·

Abstract

A chemotherapy-free induction and consolidation first-line treatment with dasatinib and blinatumomab that was based on a targeted and immunotherapeutic strategy was associated with high incidences of molecular response and survival and few toxic effects of grade 3 or higher in adults with Ph-positive ALL. (Funded by Associazione Italiana per la Ricerca sul Cancro and others; GIMEMA LAL2116 D-ALBA EudraCT number, 2016-001083-11; ClinicalTrials.gov number, NCT02744768.).

Topics & Keywords

Acute Lymphoblastic Leukemia research Chronic Myeloid Leukemia Treatments Chronic Lymphocytic Leukemia Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 383, Issue 17, pp. 1613-1623

DOI: 10.1056/nejmoa2016272

Field-Weighted Citation Impact: 49.74